Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
But how viable is Kickstarting a biopharma?
November 13, 2013
By: Michael A.
Director, Fairmount Partners
It’s been 18 months since I wrote a column about the Jumpstart Our Business Startups (JOBS) Act, which President Obama signed in April 2012. As a reminder, the purpose of that law was to “increase job creation and economic growth by improving access to the public capital markets for emerging growth companies.” (You can find that column at bit.ly/17vzF45.) Title I created an easier Initial Public Offering (IPO) on-ramp for companies meeting the new definition of an Emerging Growth Company. It was effective immediately, and has been used by several firms as they planned and executed their IPOs. Title II called on the Securities and Exchange Commission (SEC) to lift the ban on mass advertising of private placements offered to accredited investors. In July 2013, the SEC adopted a rule making that change, which became effective in September. Title III was the source of a significant change in policy; it amended the SEC rules to allow certain issuers to sell equity in a business through crowdfunding. During the past several years, that technique of raising money through the Internet had been used to attract funding for projects involving film, dance, art, design, and technology. It had not been used to raise equity in a business enterprise because doing so would have violated SEC rules. The Act gave the SEC 270 days to revise its rules to permit such funding for start-up companies. After 530 days and much deliberation, the SEC recently proposed the rules governing the process of raising money through crowdfunding. That proposal is 585 pages long; it includes more than 1,100 footnotes, and asks for comments on 295 questions. It is open to public comments for 90 days; the staff and commissioners can be expected to spend another 30-60 days evaluating those comments and preparing a final rule. So it could be March 2014 before the rules governing crowdfunding will finally be in place. What’s in the proposal? For the most part, it follows the guidelines noted in the JOBS Act.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !